Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.39) by 53.85 percent. The company reported quarterly sales of $2.482 million which missed the analyst consensus estimate of $3.800 million by 34.68 percent.
Tonix Pharmaceuticals Q1 2024 GAAP EPS $(0.18) Beats $(0.39) Estimate, Sales $2.482M Miss $3.800M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.